The PPARα agonist fenofibrate, a lipid-lowering drug, improves colitis by reducing IL-17 and IFN-γ production by Th1 and Th17 cells in IL-10 -/- KO mice, a murine model of IBD [49]. Here, PPARA is linked to irritable bowel syndrome.